Oppenheimer & Co. Inc. Purchases 9,702 Shares of CME Group Inc. $CME

Oppenheimer & Co. Inc. boosted its position in CME Group Inc. (NASDAQ:CME) by 27.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,594 shares of the financial services provider’s stock after buying an additional 9,702 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in CME Group were worth $11,683,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC grew its stake in shares of CME Group by 2,075.0% during the first quarter. Whipplewood Advisors LLC now owns 87 shares of the financial services provider’s stock valued at $26,000 after acquiring an additional 83 shares in the last quarter. First Community Trust NA acquired a new position in shares of CME Group in the third quarter worth about $26,000. North Point Portfolio Managers Corp OH acquired a new position in shares of CME Group in the third quarter worth about $26,000. Main Street Group LTD purchased a new position in CME Group in the first quarter valued at about $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in CME Group in the second quarter valued at about $28,000. 87.75% of the stock is owned by hedge funds and other institutional investors.

CME Group Price Performance

CME stock opened at $293.48 on Wednesday. The stock’s 50 day simple moving average is $278.65 and its 200 day simple moving average is $279.51. CME Group Inc. has a 12-month low of $218.31 and a 12-month high of $329.16.

CME Group (NASDAQ:CME) last released its quarterly earnings data on Wednesday, October 21st. The financial services provider reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.99 by $0.03. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.71 billion. During the same period in the prior year, the firm earned $2.68 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, sell-side analysts forecast that CME Group Inc. will post 12.34 earnings per share for the current year.

CME Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Wednesday, September 9th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date was Wednesday, September 9th.

CME Group News Summary

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: CME Group reported record third-quarter revenue of approximately $1.74 billion and record average daily volume of 29.4 million contracts. October activity is also tracking at the highest October average daily volume on record, supporting the company’s growth outlook. CME Group Slides as Investors Digest Recent Earnings and Mixed Post-Report Signals
• Positive Sentiment: Zacks upgraded CME Group to Rank #2, or “Buy,” citing improving optimism about the company’s earnings prospects. CME Upgraded to Buy: Here’s Why
• Positive Sentiment: Brazilian real futures traded a record daily volume following Brazil’s election, highlighting demand for CME’s products during periods of political and currency-market volatility. CME Group Brazilian Real Futures Set New Daily Volume Record Following Election
• Neutral Sentiment: Analyst price targets remain mixed, with a reported median target of $305 and recent targets ranging from $260 to $323, indicating support for the business but limited consensus on near-term upside.
• Negative Sentiment: Investors may be digesting last week’s earnings announcement after a significant share-price run-up. Although results were strong, they may not have exceeded elevated expectations enough to sustain momentum, prompting profit-taking or a valuation reset. CME Group Slides as Investors Digest Recent Earnings and Mixed Post-Report Signals
• Negative Sentiment: Insider Sunil Cutinho sold 5,000 shares worth approximately $1.49 million, reducing his direct holdings by nearly 20%. The transaction is a modest sentiment negative, although one insider sale does not necessarily indicate a change in CME’s fundamentals. Sunil Cutinho Insider Trading Activity

Insider Buying and Selling

In related news, Director Martin J. Gepsman sold 400 shares of the business’s stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $302.50, for a total transaction of $121,000.00. Following the completion of the sale, the director owned 25,244 shares of the company’s stock, valued at $7,636,310. This represents a 1.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elizabeth A. Cook sold 500 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $280.11, for a total transaction of $140,055.00. Following the sale, the director owned 17,916 shares in the company, valued at approximately $5,018,450.76. This trade represents a 2.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 20,900 shares of company stock worth $5,871,155. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CME shares. UBS Group raised their price objective on CME Group from $270.00 to $310.00 and gave the company a “neutral” rating in a research note on Thursday, October 22nd. JPMorgan Chase & Co. raised CME Group from an “underweight” rating to an “overweight” rating and set a $367.00 target price on the stock in a research report on Thursday, October 22nd. Weiss Ratings raised CME Group from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Raymond James Financial reiterated an “outperform” rating and set a $320.00 target price on shares of CME Group in a research note on Thursday, July 2nd. Finally, Wall Street Zen raised shares of CME Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 3rd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $313.29.

CME Group Profile

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for futures and options contracts. Its products cover major asset classes, including interest rates, equity indexes, foreign currencies, agricultural commodities, energy and metals. The company also provides market data, benchmark information and related services used by financial institutions, corporations, producers, investors and other market participants.

CME Group’s exchange portfolio includes CME, the Chicago Board of Trade, the New York Mercantile Exchange and COMEX.